News from BioTrends Research Group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 19, 2013, 10:00 ET Although Physicians' Overall Impressions on the Dialysis Bundle are More Positive, Cost Concerns Remain High, Especially as Dialysis Units Prepare for Continued Changes

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in Q4 2013...


Dec 19, 2013, 08:00 ET According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...


Dec 12, 2013, 10:00 ET Surveyed Neurologists Report Significantly Higher Relapsing-Remitting Multiple Sclerosis Patient Shares for Gilenya and Tysabri, Compared With One Year Ago

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...


Dec 10, 2013, 08:00 ET At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...


Dec 09, 2013, 12:00 ET At Twelve Months Post-Launch, the Majority of Surveyed Oncologists Have Prescribed Xtandi to Their Docetaxel-Pretreated Metastatic Castrate-Resistant Prostate Cancer Patients

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at 12...


Dec 09, 2013, 10:23 ET At One Month Post-Launch, More than One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Boehringer Ingelheim's Gilotrif for Non-Small-Cell Lung Cancer

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, one...


Dec 03, 2013, 09:00 ET Most Rheumatologists Believe that a Steroid-Sparing Effect Would Be an Important Benefit of a New Drug for Systemic Lupus Erythematosus (SLE)

BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 80 percent...


Dec 02, 2013, 09:00 ET According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...


Nov 26, 2013, 09:00 ET According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...


Nov 25, 2013, 11:29 ET Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzyme's Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...


Nov 21, 2013, 09:00 ET Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gilead's Sofosbuvir and Janssen/Medivir's Simeprevir

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...


Oct 31, 2013, 10:20 ET Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among...


Oct 31, 2013, 08:00 ET The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies Within 12 Months Of Launch

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed...


Oct 30, 2013, 09:00 ET More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, while...


Oct 30, 2013, 09:00 ET Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis

 BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...


Oct 23, 2013, 09:00 ET Humira and Simponi Have Been Prescribed By Significantly More U.S. Gastroenterologists in 2013 than in 2012, Likely Owing to Their Recent Approvals for Ulcerative Colitis

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds...


Oct 22, 2013, 11:43 ET At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at one...


Oct 17, 2013, 09:00 ET Nearly Half of Surveyed European Retinal Specialists Currently Treat Wet AMD Patients with Bayer's Eylea Eight Months after Its Approval

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, eight...


Oct 16, 2013, 08:00 ET Endocrinologists Would Prefer Extensive Efficacy Data Before Prescribing Biosimilar Insulins

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S....


Oct 01, 2013, 09:56 ET Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among...


Sep 30, 2013, 11:00 ET Gastroenterologists Unlikely To Use Celltrion/Hospira's Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority...


Sep 25, 2013, 09:00 ET According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according...


Sep 24, 2013, 09:00 ET Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed...


Sep 19, 2013, 09:00 ET Enbrel and Humira Remain the Mainstay for First-Line Biologic Rheumatoid Arthritis Treatment

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the...


Sep 16, 2013, 09:00 ET At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at one...